{
    "clinical_study": {
        "@rank": "53599", 
        "acronym": "MILEPOST", 
        "arm_group": [
            {
                "arm_group_label": "g-Cath EZ Treatment Group", 
                "arm_group_type": "Experimental", 
                "description": "Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention"
            }, 
            {
                "arm_group_label": "Diet and exercise Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Diet and Exercise only control group"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the\n      safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight\n      loss intervention compared to a diet and exercise control only.  Mean % Total Body Weight\n      Loss [TBWL] in Treatment subjects versus that of Control subjects at 12 months is the\n      primary endpoint.  The proportion of subjects achieving \u2265 5% TBWL at 12 months in the\n      treatment group is a co-primary endpoint."
        }, 
        "brief_title": "Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "This study will evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor\n      Delivery Catheter as an early weight loss intervention compared to a diet and exercise\n      control only.  The weight loss outcomes will be used to assess treatment effect. This study\n      is a multi-center, open/unblinded, prospective randomized feasibility study (3:1Treatment:\n      Control) study. Patients in the control group will be offered the opportunity to crossover\n      to the treatment group at 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 20-60 years\n\n          -  Body Mass Index [BMI] of >30 and <40 with or without a co-morbid condition\n\n          -  Subject has failed more conservative weight reduction alternatives such as supervised\n             diet, exercise or behavior modification programs in the last year\n\n          -  No significant weight change (+/- 5% of total body weight) in last  6 months\n\n          -  American Society Anesthesiologists-Physical Status score  \u2264 2 (Appendix III),\n\n          -  Subject agrees not to have any additional weight loss interventional procedures or\n             liposuction for at least 30 months following study enrollment,\n\n          -  Has not taken any prescription or over the counter weight loss medications for at\n             least 6 months,\n\n          -  Signed informed consent.\n\n          -  Subject is willing to cooperate with post-operative dietary recommendations and\n             assessment tests,\n\n        Exclusion Criteria:\n\n          -  History of (or intraoperative evidence of) bariatric, gastric or esophageal surgery\n\n          -  Esophageal stricture or other anatomy and/or condition that could preclude passage of\n             endolumenal instruments\n\n          -  Severe gastroesophageal reflux disease (GERD), defined as symptoms that cause subject\n             severe discomfort, compromise performance of daily activities, and/or condition is\n             not entirely controlled with prescription drug therapy\n\n          -  Known hiatal hernia >3 centimeters by history or as determined by Upper\n             Gastrointestinal exam or endoscopy\n\n          -  Pancreatic insufficiency/disease\n\n          -  Active peptic ulcer\n\n          -  Pregnancy or plans of pregnancy in the next 12 months\n\n          -  Present Corticosteroid Use\n\n          -  History of inflammatory disease of Gastrointestinal [GI] tract; Coagulation\n             disorders; hepatic insufficiency or cirrhosis\n\n          -  History or present use of insulin or insulin derivatives for treatment of diabetes\n\n          -  Type II Diabetes Mellitus [DM] (as defined by Glycosylated Hemoglobin [HgbA1c] >6.5)\n             for greater than 2 years at the time of enrollment\n\n          -  Uncontrolled Type II DM (HgbA1c > 7.0 at screening)\n\n          -  Quit smoking within last 6 months at time of enrollment or plans to quit smoking in\n             the next year\n\n          -  Immunosuppression\n\n          -  Portal hypertension and/or varices\n\n          -  Active gastric ulcer disease\n\n          -  Gastric outlet obstruction or stenosis\n\n          -  Beck Depression Inventory (Short) Score \u226512 (see Appendix IV);\n\n          -  Subject has a history of drug or alcohol abuse or actively abusing either as defined\n             by Cage and DAST [drug use] questionnaires or positive Urinalysis [UA] drug screen\n\n          -  Severe disturbances in eating behavior (i.e. binge eating)\n\n          -  Known presence of a significant depression, psychosis, or other mood or eating\n             disorder\n\n          -  Actively treated depression (except for stable treated depression for >1year and\n             normal [Beck Depression Inventory [BDI] and psych exam)\n\n          -  Present or past history of psychosis or other mood or eating disorder\n\n          -  Non-ambulatory or has significant impairment of mobility\n\n          -  Known hormonal or genetic cause for obesity with the exception of treated\n             hypothyroidism.\n\n          -  Participating in another clinical study\n\n          -  Is a first degree relative of investigator, or support staff involved in the study.\n\n          -  Employed by investigator or institution involved in the study\n\n          -  Subject is not able to provide written informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843231", 
            "org_study_id": "41936"
        }, 
        "intervention": [
            {
                "arm_group_label": "g-Cath EZ Treatment Group", 
                "description": "Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group", 
                "intervention_name": "g-CathTM EZ Suture Anchor Delivery Catheter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Diet and exercise Control Group", 
                "description": "Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group", 
                "intervention_name": "Diet and Exercise Control Group", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "g-Cath EZ Suture Anchor Delivery Catheter", 
            "Weight Loss Intervention"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "karl.miller@kh-hallein.at", 
                    "last_name": "Karl Miller, MD, FACS", 
                    "phone": "+43 6245 799-360"
                }, 
                "facility": {
                    "address": {
                        "city": "Hallein", 
                        "country": "Austria", 
                        "state": "Salzburg"
                    }, 
                    "name": "Krakenhaus Hallein"
                }, 
                "investigator": {
                    "last_name": "Karl Miller, MD, FACS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.greve@atriummc.nl", 
                    "last_name": "J.W. M Greve, MD, PhD", 
                    "phone": "+31 45 576 65 99"
                }, 
                "facility": {
                    "address": {
                        "city": "Heerlen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Atrium Medical Centre"
                }, 
                "investigator": {
                    "last_name": "J.W. M Greve, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jorge C. Espinos, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Centro Medico Teknon"
                }, 
                "investigator": {
                    "last_name": "Jorge C. Espinos, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Multicenter Feasibility Study of an IncisionLEss Operating Platform for Primary ObeSiTy vs. Diet-exercise Alone: The MILEPOST Study", 
        "overall_contact": {
            "email": "jwhite@usgimedical.com", 
            "last_name": "James J White, D.O.", 
            "phone": "215-962-6178"
        }, 
        "overall_official": {
            "affiliation": "Centro Medico Teknon", 
            "last_name": "Jorge C. Espinos, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Salzburg, Austria: Ethikkommission for the Bundesland Salzburg", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Incidence and severity of Adverse Events [AE] over 12 Months", 
                "measure": "Primary Safety Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Mean % TBWL at 12  months for Treatment subjects compared to Control subjects", 
                "measure": "Primary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The proportion of Treatment subjects achieving \u2265 5% TBWL at 12 months", 
                "measure": "Co-Primary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "removed_countries": {
            "country": "United Kingdom"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843231"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean % TBWL at 24 months.", 
                "measure": "First Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Proportion of subjects achieving \u2265 5% TBWL at 24 months", 
                "measure": "Second Secondary Efficacy endpoint", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Satiety changes (volume and time to satiety at 2, 6, 12 months post-procedure)", 
                "measure": "Third Secondary Efficacy endpoint", 
                "safety_issue": "No", 
                "time_frame": "2, 6, 12 months"
            }, 
            {
                "description": "% Estimated Weight Loss [EWL] at 12 months and 18 months [% EWL will be calculated using BMI-25 criteria]", 
                "measure": "Fourth Secondary Efficacy endpoint", 
                "safety_issue": "No", 
                "time_frame": "12 & 18 months"
            }
        ], 
        "source": "USGI Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "USGI Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}